Patients included in randomised controlled trials do not represent those seen in clinical practice: Focus on antimicrobial agents

International Journal of Antimicrobial Agents

Volumn 36, Issue 1, 2010, Pages 1-13

  Falagas, Matthew E ^a,b,c   Vouloumanou, Evridiki K ^a   Sgouros, Konstantinos ^a   Athanasiou, Stavros ^d   Peppas, George ^a   Siempos, Ilias I ^a  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Evidence based medicine; External validity

Indexed keywords

ADRENALIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; BECLOMETASONE DIPROPIONATE; CASPOFUNGIN; CEFUROXIME; CLOXACILLIN; COTRIMOXAZOLE; DAPTOMYCIN; DEXAMETHASONE; DORIPENEM; ETHAMBUTOL; FAMCICLOVIR; FLUCONAZOLE; GABAPENTIN; GENTAMICIN; ISONIAZID; MEROPENEM; MICAFUNGIN; MOXIFLOXACIN; OXYCODONE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; SULBACTAM; TELITHROMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIMICROBIAL THERAPY; BACTERIAL ENDOCARDITIS; BACTERIAL SINUSITIS; BLOODSTREAM INFECTION; BRONCHIOLITIS; CANDIDEMIA; CANDIDIASIS; CELLULITIS; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ERYSIPELAS; EVIDENCE BASED MEDICINE; GENERAL PRACTICE; GYNECOLOGIC INFECTION; HERPES ZOSTER; HOSPITAL INFECTION; HUMAN; INFECTION; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; MEDLINE; OSTEOMYELITIS; PATIENT SELECTION; PNEUMONIA; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFECTION; SHORT SURVEY; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS INFECTION; TUBERCULOSIS; VAGINA CANDIDIASIS;

ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASES; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77953024864     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.03.020     Document Type: Short Survey

References (57)

1. Concato J., Shah N., Horwitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000, 342:1887-1892.
2. Rosenberg W., Donald A. Evidence based medicine: an approach to clinical problem-solving. BMJ 1995, 310:1122-1126.
3. Fragoulis K.N., Michalopoulos A., Falagas M.E. Open-access world wide web resources on sepsis. Clin Infect Dis 2008, 47:588.
4. Siempos I.I., Fragoulis K.N., Falagas M.E. World Wide Web resources on control of nosocomial infections. Crit Care 2007, 11:101.
5. Siempos I.I., Dimopoulos G., Falagas M.E. Meta-analyses on the prevention and treatment of respiratory tract infections. Infect Dis Clin North Am 2009, 23:331-353.
6. Kollef M.H., Afessa B., Anzueto A., Veremakis C., Kerr K.M., Margolis B.D., et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA 2008, 300:805-813.
7. Karageorgopoulos D.E., Valkimadi P.E., Kapaskelis A., Rafailidis P.I., Falagas M.E. Short versus long duration of antibiotic therapy for bacterial meningitis: a meta-analysis of randomised controlled trials in children. Arch Dis Child 2009, 94:607-614.
8. Conde M.B., Efron A., Loredo C., De Souza G.R., Graça N.P., Cezar M.C., et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009, 373:1183-1189.
9. Dworkin R.H., Barbano R.L., Tyring S.K., Betts R.F., McDermott M.P., Pennella-Vaughan J., et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain 2009, 142:209-217.
10. Ermers M.J., Rovers M.M., van Woensel J.B., Kimpen J.L., Bont L.J. The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial. BMJ 2009, 338:b897.
11. Euba G., Murillo O., Fernández-Sabé N., Mascaró J., Cabo J., Pérez A., et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother 2009, 53:2672-2676.
12. Plint A.C., Johnson D.W., Patel H., Wiebe N., Correll R., Brant R., et al. Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med 2009, 360:2079-2089.
13. Rehm S., Campion M., Katz D.E., Russo R., Boucher H.W. Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy. J Antimicrob Chemother 2009, 63:1034-1042.
14. Pertel P.E., Eisenstein B.I., Link A.S., Donfrid B., Biermann E.J., Bernardo P., et al. The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract 2009, 63:368-375.
15. Pareek A., Pednekar S., Prasad H.B., Salagre S., Chandurkar N. Randomized, multicentre, comparative clinical evaluation of cefuroxime-sulbactam versus amoxicillin-clavulanic acid therapy in the treatment of lower respiratory tract infections. J Int Med Res 2008, 36:1293-1304.
16. Desrosiers M., Ferguson B., Klossek J.M., Drugeon H., Mosges R. Clinical efficacy and time to symptom resolution of 5-day telithromycin versus 10-day amoxicillin-clavulanate in the treatment of acute bacterial sinusitis. Curr Med Res Opin 2008, 24:1691-1702.
17. Lucasti C., Jasovich A., Umeh O., Jiang J., Kaniga K., Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008, 30:868-883.
18. Martinez R.C., Franceschini S.A., Patta M.C., Quintana S.M., Candido R.C., Ferreira J.C., et al. Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. Lett Appl Microbiol 2009, 48:269-274.
19. Noel G.J., Blumer J.L., Pichichero M.E., Hedrick J.A., Schwartz R.H., Balis D.A., et al. A randomized comparative study of levofloxacin versus amoxicillin/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media. Pediatr Infect Dis J 2008, 27:483-489.
20. Pappas P.G., Rotstein C.M., Betts R.F., Nucci M., Talwar D., De Waele J.J., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883-893.
21. Réa-Neto A., Niederman M., Lobo S.M., Schroeder E., Lee M., Kaniga K., et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008, 24:2113-2126.
22. Talbot G.H., Thye D., Das A., Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007, 51:3612-3616.
23. Malangoni M.A., Song J., Herrington J., Choudhri S., Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006, 244:204-211.
24. Finch R., Schürmann D., Collins O., Kubin R., McGivern J., Bobbaers H., et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002, 46:1746-1754.
25. Sher L.D., McAdoo M.A., Bettis R.B., Turner M.A., Li N.F., Pierce P.F. A multicenter, randomized, investigator-blinded study of 5- and 10-day gatifloxacin versus 10-day amoxicillin/clavulanate in patients with acute bacterial sinusitis. Clin Ther 2002, 24:269-281.
26. Alvarez-Lerma F., Insausti-Ordeñana J., Jordá-Marcos R., Maraví-Poma E., Torres-Martí A., Nava J., et al. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med 2001, 27:493-502.
27. Siami G., Christou N., Eiseman I., Tack K.J. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother 2001, 45:525-531.
28. File T., Schlemmer B., Garau J., Lode H., Lynch S., Young C. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group. J Chemother 2000, 12:314-325.
29. Schouenborg P., Gerdes N., Rasmussen H., Wickers-Nielsen N., Mathiassen E. Azithromycin versus pivampicillin in the treatment of acute exacerbations of chronic bronchitis: a single-blind, double-dummy, multicentre study. J Int Med Res 2000, 28:101-110.
30. Cohn S.M., Lipsett P.A., Buchman T.G., Cheadle W.G., Milsom J.W., O'Marro S., et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000, 232:254-262.
31. Joshi M., Bernstein J., Solomkin J., Wester B.A., Kuye O. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group. J Antimicrob Chemother 1999, 43:389-397.
32. Brun-Buisson C., Sollet J.P., Schweich H., Briere S., Petit C. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group. Clin Infect Dis 1998, 26:346-354.
33. Scheinin H., Havia T., Pekkala E., Huovinen P., Klossner J., Lehto H., et al. Aspoxicillin versus piperacillin in severe abdominal infections-a comparative phase III study. J Antimicrob Chemother 1994, 34:813-817.
34. Sweet R.L., Roy S., Faro S., O'Brien W.F., Sanfilippo J.S., Seidlin M. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. The Piperacillin/tazobactam Study Group. Obstet Gynecol 1994, 83:280-286.
35. Klietmann W., Cesana M., Rondel R.K., Focht J. Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis. Antimicrob Agents Chemother 1993, 37:2298-2306.
36. Brambilla C., Kastanakis S., Knight S., Cunningham K. Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1992, 11:118-124.
37. Lousbergh D., Jochems G., Everaert L., Puttemans M. Roxithromycin versus amoxicillin-clavulanic acid in the treatment of respiratory tract infections. Diagn Microbiol Infect Dis 1992, 15(4 Suppl.):91S-95S.
38. Sackett D.L., Rosenberg W.M. The need for evidence-based medicine. J R Soc Med 1995, 88:620-624.
39. Feinstein A.R., Horwitz R.I. Problems in the 'evidence' of 'evidence-based medicine'. Am J Med 1997, 103:529-535.
40. Jacobson L.D., Edwards A.G., Granier S.K., Butler C.C. Evidence-based medicine and general practice. Br J Gen Pract 1997, 47:449-452.
41. Britton A., McKee M., Black N., McPherson K., Sanderson C., Bain C. Threats to applicability of randomised trials: exclusions and selective participation. J Health Serv Res Policy 1999, 4:112-121.
42. Falagas M.E., Rafailidis P.I., Rosmarakis E.S. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007, 29:374-379.
43. Wysowski D.K., Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005, 165:1363-1369.
44. Bottone F.G., Barry W.T. Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002. Curr Med Res Opin 2009, 25:1535-1550.
45. Garfield F.B., Caro J.J. Postmarketing studies: benefits and risks. Value Health 1999, 2:295-307.
46. Garg A.X., Mamdani M., Juurlink D.N., van Walraven C. Identifying individuals with a reduced GFR using ambulatory laboratory database surveillance. J Am Soc Nephrol 2005, 16:1433-1439.
47. Garg A.X., Papaioannou A., Ferko N., Campbell G., Clarke J.A., Ray J.G. Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int 2004, 65:649-653.
48. Ryan T.P., Sloand J.A., Winters P.C., Corsetti J.P., Fisher S.G. Chronic kidney disease prevalence and rate of diagnosis. Am J Med 2007, 120:981-986.
49. Clark J.M., Brancati F.L., Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98:960-967.
50. Freedman L.S., Simon R., Foulkes M.A., Friedman L., Geller N.L., Gordon D.J., et al. Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993-the perspective of NIH clinical trialists. Control Clin Trials 1995, 16:277-285.
51. Gurwitz J.H., Col N.F., Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA 1992, 268:1417-1422.
52. Hall W.D. Representation of Blacks, women, and the very elderly (aged ≥80) in 28 major randomized clinical trials. Ethn Dis 1999, 9:333-340.
53. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A., Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341:2061-2067.
54. Bennett J.C. Inclusion of women in clinical trials-policies for population subgroups. N Engl J Med 1993, 329:288-292.
55. Iannini P.B. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Curr Med Res Opin 2007, 23:1403-1413.
56. Walson P.D. Therapeutic drug monitoring in special populations. Clin Chem 1998, 44:415-419.
57. Yoshikawa K., Davies A. Safety of ProHance in special populations. Eur Radiol 1997, 7(Suppl. 5):246-250.